keyword
MENU ▼
Read by QxMD icon Read
search

zoledronic

keyword
https://www.readbyqxmd.com/read/28645291/the-effect-of-zoledronic-acid-on-type-and-volume-of-modic-changes-among-patients-with-low-back-pain
#1
Katri Koivisto, Jyri Järvinen, Jaro Karppinen, Marianne Haapea, Markus Paananen, Eero Kyllönen, Osmo Tervonen, Jaakko Niinimäki
BACKGROUND: Modic changes (MC) are associated with low back pain (LBP). In this study, we compared changes in size and type of MC, after a single intravenous infusion of 5 mg zoledronic acid (ZA) or placebo, among chronic LBP patients with MC on magnetic resonance imaging (MRI), and evaluated whether the MRI changes correlate with symptoms. METHODS: All patients (N = 19 in ZA, 20 in placebo) had MRI at baseline (0.23-1.5 T) and at one year (1.5-3 T). We evaluated the level, type and volume of all the MC...
June 23, 2017: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/28644302/the-role-of-bone-targeted-therapies-for-prostate-cancer-in-2017
#2
Samer L Traboulsi, Fred Saad
PURPOSE OF REVIEW: Bone-targeted agents (BTAs), such as zoledronic acid and denosumab, delay the occurrence of skeletal-related events (SREs) in metastatic prostate cancer (PCa) patients. Recently, several agents, such as abiraterone acetate, enzalutamide and radium-223, were approved for the treatment of metastatic castration-resistant PCa (mCRPC). These agents resulted in improved overall survival (OS), pain control and had positive effects on bone health. Combining BTAs to the newly approved agents demonstrates additional benefits that warrant a review of available evidence looking at appropriate combination therapies and timing of BTAs for optimizing the management of advanced and metastatic PCa...
July 20, 2017: Current Opinion in Supportive and Palliative Care
https://www.readbyqxmd.com/read/28643933/oncologic-doses-of-zoledronic-acid-induce-site-specific-suppression-of-bone-modelling-in-rice-rats
#3
C R Exposto, U Oz, J S Callard, M J Allen, H Khurana, A D' Atri, X Mo, S A Fernandez, D N Tatakis, K Edmonds, P M Westgate, S S Huja
OBJECTIVES: To examine the effect of zoledronic acid (ZOL) on cortical bone modelling and healing of extraction sockets in the jaw bones of a rodent model. We hypothesized ZOL suppresses both the bone formation in the modelling mode in the jaw bones and alters the extraction site healing. MATERIAL & METHODS: Rice rats were administered saline solution and two dose regimens of ZOL: 0.1 mg/kg, twice a week, for 4 weeks (n=17, saline=8 & ZOL=9) and a higher dose of 0...
June 2017: Orthodontics & Craniofacial Research
https://www.readbyqxmd.com/read/28641180/potential-chemotherapeutic-effects-of-diosgenin-zoledronic-acid-and-epigallocatechin-3-gallate-on-pe-ca-pj15-oral-squamous-cancer-cell-line
#4
Eduardo Pons-Fuster López, Qin-Tong Wang, Wei Wei, Pia López Jornet
OBJECTIVE: To study the potential chemotherapeutic effects of Diosgenin, zoledronic acid and Epigallocatechin-3-gallate on oral squamous cell cancer (OSCC). MATERIALS AND METHODS: Cell viability, migration, apoptosis and cell cycle evaluation assays were performed in order to assess the effects of different doses of Diosgenin, zoledronic acid and Epigallocatechin-3-gallate on the PE/CA-PJ15 cell line. RESULTS: Doses of 100μM of diosgenin or zoledronic acid reduced cell viability significantly after 72h (p<0...
June 19, 2017: Archives of Oral Biology
https://www.readbyqxmd.com/read/28639571/recurrence-factors-in-giant-cell-tumors-of-the-spine
#5
Han-Qiang Ouyang, Liang Jiang, Xiao-Guang Liu, Feng Wei, Shao-Min Yang, Na Meng, Ping Jiang, Miao Yu, Feng-Liang Wu, Lei Dang, Hua Zhou, Hua Zhang, Zhong-Jun Liu
BACKGROUND: Giant cell tumors (GCTs) are benign, locally aggressive tumors. We examined the rate of local recurrence of spinal GCTs and sought to identify recurrence factors in patients who underwent surgery. METHODS: Between 1995 and 2014, 94 mobile spine GCT patients were treated at our hospital, comprising 43 male and 51 female patients with an average age of 33.4 years. Piecemeal intralesional spondylectomy and total en bloc spondylectomy (TES) were performed...
July 5, 2017: Chinese Medical Journal
https://www.readbyqxmd.com/read/28638344/the-beneficial-effects-of-bisphosphonate-enoxacin-on-cortical-bone-mass-and-strength-in-ovariectomized-rats
#6
Xuqiang Liu, Xinhua Qu, Tao Nie, Zanjing Zhai, Haowei Li, Zhengxiao Ouyang, An Qin, Shuhong Zhang, Shuangyan Zhang, Qiming Fan, Tingting Tang, Zhifeng Yu, Min Dai
Osteoporosis is a major age-related bone disease characterized by low bone mineral density and a high risk of fractures. Bisphosphonates are considered as effective agents treating osteoporosis. However, long-term use of bisphosphonates is associated with some serious side effects, which limits the widespread clinical use of bisphosphonates. Here, we demonstrate a novel type of bone-targeting anti-resorptive agent, bisphosphonate-enoxacin (BE). In this study, ovariectomized rat model was established and treated with PBS, zoledronate (50 μg/kg) and different dose of BE (5 mg/kg and 10 mg/kg), respectively...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28637206/improving-combination-osteoporosis-therapy-in-a-preclinical-model-of-heightened-osteoanabolism
#7
Yu Shao, Selene Hernandez-Buquer, Paul Childress, Keith R Stayrook, Marta B Alvarez, Hannah Davis, Lilian Plotkin, Yongzheng He, Keith W Condon, David B Burr, Stuart J Warden, Alexander G Robling, Feng-Chun Yang, Ronald C Wek, Matthew R Allen, Joseph P Bidwell
Combining anti-catabolic agents with parathyroid hormone (PTH) to enhance bone mass has yielded mixed results in osteoporosis patients. Towards the goal of enhancing the efficacy of these regimens, we tested their utility in combination with loss of the transcription factor Nmp4 since disabling this gene amplifies PTH-induced increases in trabecular bone in mice by boosting osteoblast secretory activity. We addressed whether combining a sustained anabolic response with an anti-catabolic results in superior bone acquisition compared to PTH mono-therapy...
June 20, 2017: Endocrinology
https://www.readbyqxmd.com/read/28631925/anticancer-activity-of-polyoxometalate-bisphosphonate-complexes-synthesis-characterization-in-vitro-and-in-vivo-results
#8
Amandine Boulmier, Xinxin Feng, Olivier Oms, Pierre Mialane, Eric Rivière, Christopher J Shin, Jiaqi Yao, Tadahiko Kubo, Taisuke Furuta, Eric Oldfield, Anne Dolbecq
We synthesized a series of polyoxometalate-bisphosphonate complexes containing Mo(VI)O6 octahedra, zoledronate, or an N-alkyl (n-C6 or n-C8) zoledronate analogue, and in two cases, Mn as a heterometal. Mo6L2 (L = Zol, ZolC6, ZolC8) and Mo4L2Mn (L = Zol, ZolC8) were characterized by using single-crystal X-ray crystallography and/or IR spectroscopy, elemental and energy dispersive X-ray analysis and (31)P NMR. We found promising activity against human nonsmall cell lung cancer (NCI-H460) cells with IC50 values for growth inhibition of ∼5 μM per bisphosphonate ligand...
June 20, 2017: Inorganic Chemistry
https://www.readbyqxmd.com/read/28628088/an-individualised-risk-adapted-protocol-of-pre-and-post-transplant-zoledronic-acid-reduces-bone-loss-after-allogeneic-stem-cell-transplantation-results-of-a-phase-ii-prospective-trial
#9
A Grigg, B Butcher, B Khodr, A Bajel, M Hertzberg, S Patil, A B D'Souza, P Ganly, P Ebeling, E Wong
Bone loss occurs frequently following allogeneic haematopoietic stem cell transplantation (alloSCT). The Australasian Leukaemia and Lymphoma Group conducted a prospective phase II study of pretransplant zoledronic acid (ZA) and individualised post-transplant ZA to prevent bone loss in alloSCT recipients. Patients received ZA 4 mg before conditioning. Administration of post-transplant ZA from days 100 to 365 post alloSCT was determined by a risk-adapted algorithm based on serial bone density assessments and glucocorticoid exposure...
June 19, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28626914/synthesis-preclinical-and-pharmacokinetic-evaluation-of-a-new-zoledronate-derivative-as-a-promising-antiosteoporotic-candidate-using-radiolabeling-technique
#10
H A Motaleb, I T Ibrahim, M El-Tawoosy, M I Mohamed
A novel zoledronic acid (ZL) derivative, 3-(2-ethyl-4-methyi-1H-imidazole-1-yl)-1-hydroxy-1-phosphonopropyl phosphonic acid (EMIHPBP), was synthesized, characterized and successfully radiolabeled with (99m) Tc. The in-vivo biodistribution of (99m) Tc-EMIHPBP was investigated and compared with the previously reported zoledronate derivatives aiming to formulate a novel zoledronate derivative with a high potential uptake to bone as a promising antiosteoporotic candidate. In order to further evaluate the bone uptake efficiency, the pharmacokinetics of (99m) Tc-EMIHPBP was investigated, and showed that maximum concentration in bone (Cmax ) was 31...
June 18, 2017: Journal of Labelled Compounds & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28622548/early-bony-changes-associated-with-bisphosphonate-related-osteonecrosis-of-the-jaws-in-rats-a-longitudinal-in-vivo-study
#11
Josy Lorena Peres Vilarinho, Nathália Ferrare, Andreia Maria Rocha Moreira, Helora Freitas Moura, Ana Carolina Acevedo, Sacha Braun Chaves, Nilce Santos Melo, André Ferreira Leite, Sérgio Bruzadelli Macedo, Melissa Paoletti de Souza, Ana Tereza Bittencourt Guimarães, Paulo Tadeu Figueiredo
OBJECTIVE: To evaluate early bony changes in an animal model of Medication-Related Osteonecrosis of the Jaw (MRONJ) at the side of the local trauma and at the contralateral side, comparing with a control group. Bony changes were evaluated by Microcomputed Tomography (MicroCT) at three times points: at baseline (T0), after drug administration (T1) and after dental extraction (T2). DESIGN: Two groups were compared: the experimental group in which zoledronic acid (ZA) was administered (17 rats) and the control group (13 rats)...
June 6, 2017: Archives of Oral Biology
https://www.readbyqxmd.com/read/28620780/a-novel-large-fragment-deletion-in-pls3-causes-rare-x-linked-early-onset-osteoporosis-and-response-to-zoledronic-acid
#12
F Lv, M Ma, W Liu, X Xu, Y Song, L Li, Y Jiang, O Wang, W Xia, X Xing, Z Qiu, M Li
We identified a novel large fragment deletion from intron 9 to 3'UTR in PLS3 (E10-E16del) in one Chinese boy with X-linked early-onset osteoporosis and vertebral fractures, which expanded the pathogenic spectrum of X-linked early-onset osteoporosis. Treatment with zoledronic acid was beneficial for increasing BMD and reshaping the vertebral bodies of this patient. INTRODUCTION: X-linked early-onset osteoporosis is a rare disease, which is characterized by low bone mineral density (BMD), vertebral compression fractures (VCFs), and/or long bone fractures...
June 16, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28618241/use-of-adjuvant-bisphosphonates-and-other-bone-modifying-agents-in-breast-cancer-a-cancer-care-ontario-and-american-society-of-clinical-oncology-clinical-practice-guideline
#13
Sukhbinder Dhesy-Thind, Glenn G Fletcher, Phillip S Blanchette, Mark J Clemons, Melissa S Dillmon, Elizabeth S Frank, Sonal Gandhi, Rasna Gupta, Mihaela Mates, Beverly Moy, Ted Vandenberg, Catherine H Van Poznak
Purpose To make recommendations regarding the use of bisphosphonates and other bone-modifying agents as adjuvant therapy for patients with breast cancer. Methods Cancer Care Ontario and ASCO convened a Working Group and Expert Panel to develop evidence-based recommendations informed by a systematic review of the literature. Results Adjuvant bisphosphonates were found to reduce bone recurrence and improve survival in postmenopausal patients with nonmetastatic breast cancer. In this guideline, postmenopausal includes patients with natural menopause or that induced by ovarian suppression or ablation...
June 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28608802/enhanced-osteogenic-differentiation-in-zoledronate-treated-osteoporotic-patients
#14
Luca Dalle Carbonare, Monica Mottes, Giovanni Malerba, Antonio Mori, Martina Zaninotto, Mario Plebani, Alessandra Dellantonio, Maria Teresa Valenti
Bisphosphonates are well known inhibitors of osteoclast activity and thus may be employed to influence osteoblast activity. The present study was designed to evaluate the in vivo effects of zoledronic acid (ZA) on the proliferation and osteoblastic commitment of mesenchymal stem cells (MSC) in osteoporotic patients. We studied 22 postmenopausal osteoporotic patients. Densitometric, biochemical, cellular and molecular data were collected before as well as after 6 and 12 months of ZA treatment. Peripheral blood MSC-like cells were quantified by colony-forming unit fibroblastic assay; their osteogenic differentiation potential was evaluated after 3 and 7 days of induction, respectively...
June 13, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28605733/the-association-between-fever-and-prognosis-in-lung-cancer-patients-with-bone-metastases-receiving-zoledronic-acid
#15
Tomiko Sunaga, Kazushi Shimamoto, Shoko Nakamura, Noriko Takahashi, Mayumi Higashino, Tomomi Hozumi, Mitsuki Matsui, Akiko Nagatani, Fumio Kokubu, Mari Kogo, Tadanori Sasaki
Zoledronic acid is an established agent used in the management of metastatic bone disease. The administration of zoledronic acid improves overall survival (OS) of lung cancer patients with bone metastases receiving chemotherapy. However, it is currently unknown whether zoledronic acid-induced fever is associated with OS. The purpose of this study was to examine the association between zoledronic acid-induced fever and prognosis in lung cancer patients with bone metastases. We retrospectively analyzed 98 lung cancer patients with bone metastases who had received zoledronic acid...
June 13, 2017: Chemotherapy
https://www.readbyqxmd.com/read/28604257/genetic-factors-related-with-early-onset-of-osteonecrosis-of-the-jaw-in-patients-with-multiple-myeloma-under-zoledronic-acid-therapy
#16
Efstathios Kastritis, Pelagia Melea, Tina Bagratuni, Ioannis Melakopoulos, Maria Gavriatopoulou, Maria Roussou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Evangelos Terpos, Meletios A Dimopoulos
Specific genetic polymorphisms (SNPs) have been correlated with the development of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in small series. We screened 140 myeloma patients (36 patients with and 104 without BRONJ) for the presence of previously identified SNPs in PPARG and CYP2C8 genes. All the patients received exclusively zolendronic acid (ZA) therapy and were followed prospectively for BRONJ. SNPs in both genes were associated with a higher risk of development of early BRONJ, occurring within less than 2 years of ZA therapy (59% vs...
June 11, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28598810/the-prevention-of-fragility-fractures-in-patients-with-non-metastatic-prostate-cancer-a-position-statement-by-the-international-osteoporosis-foundation
#17
REVIEW
Luisella Cianferotti, Francesco Bertoldo, Marco Carini, John A Kanis, Alberto Lapini, Nicola Longo, Giuseppe Martorana, Vincenzo Mirone, Jean-Yves Reginster, Rene Rizzoli, Maria Luisa Brandi
Androgen deprivation therapy is commonly employed for the treatment of non-metastatic prostate cancer as primary or adjuvant treatment. The skeleton is greatly compromised in men with prostate cancer during androgen deprivation therapy because of the lack of androgens and estrogens, which are trophic factors for bone. Men receiving androgen deprivation therapy sustain variable degrees of bone loss with an increased risk of fragility fractures. Several bone antiresorptive agents have been tested in randomized controlled trials in these patients...
May 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28594896/zoledronate-suppressed-angiogenesis-and-osteogenesis-by-inhibiting-osteoclasts-formation-and-secretion-of-pdgf-bb
#18
Si-Yong Gao, Guang-Sen Zheng, Lin Wang, Yu-Jie Liang, Si-En Zhang, Xiao-Mei Lao, Kan Li, Gui-Qing Liao
PURPOSE: Bisphosphonates related osteonecrosis of jaw (BRONJ) is a severe complication of systemic BPs administration, the mechanism of which is still unclarified. Recently, platelet-derived growth factor-BB (PDGF-BB) secreted by preosteoclasts was reported to promote angiogenesis and osteogenesis. This study aimed to clarify whether bisphosphonates suppressed preosteoclasts releasing PDGF-BB, and whether the suppression harmed coupling of angiogenesis and osteogenesis, which could contribute to BRONJ manifestation...
2017: PloS One
https://www.readbyqxmd.com/read/28580927/the-atp-binding-cassette-transporter-a1-regulates-phosphoantigen-release-and-v%C3%AE-9v%C3%AE-2-t-cell-activation-by-dendritic-cells
#19
Barbara Castella, Joanna Kopecka, Patrizia Sciancalepore, Giorgia Mandili, Myriam Foglietta, Nico Mitro, Donatella Caruso, Francesco Novelli, Chiara Riganti, Massimo Massaia
Vγ9Vδ2 T cells are activated by phosphoantigens, such as isopentenyl pyrophosphate (IPP), which is generated in the mevalonate pathway of antigen-presenting cells. IPP is released in the extracellular microenvironment via unknown mechanisms. Here we show that the ATP-binding cassette transporter A1 (ABCA1) mediates extracellular IPP release from dendritic cells (DC) in cooperation with apolipoprotein A-I (apoA-I) and butyrophilin-3A1. IPP concentrations in the supernatants are sufficient to induce Vγ9Vδ2 T cell proliferation after DC mevalonate pathway inhibition with zoledronic acid (ZA)...
June 5, 2017: Nature Communications
https://www.readbyqxmd.com/read/28579148/effect-of-time-of-administration-of-teriparatide-on-bone-mineral-density-in-glucocorticoid-induced-osteoporosis
#20
Silvina R Mastaglia
Teriparatide (TPTD) (recombinant DNA origin human parathormone [1-34]) is approved for the treatment of glucocorticoid-induced osteoporosis (GIO). There are reports of factors that affect the response to TPTD in GIO treatment. This work describes the case of a 71-yr-old woman diagnosed with lupus nephropathy treated with 40 mg/d of meprednisone, and who suffered multiple vertebral fractures. Despite treatment with a single 5 mg dose of zoledronic acid, the patient continued to have vertebral fractures. Treatment with 20 µg/d of subcutaneous TPTD (PTH1-34, Forteo; Eli Lilly Co...
June 1, 2017: Journal of Clinical Densitometry
keyword
keyword
113547
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"